Radiation Therapy for Favorable Intermediate Risk Prostate Cancer w/ Dr. Amar Kishan | Ep. 53 For more info, visit: Parallel Phase III Randomized Trials Of
Presented by Jeff Michalski, MD, MBA, FASTRO Carlos A. Perez Distinguished Professor Vice Chair of Radiation Oncology Chair Applying a Clinical Genomic Nomogram for ADT Decisions in Intermediate Risk Prostate Cancer
Understanding Prostate Cancer - Intermediate Risk Intermediate risk disease commonly contains aggressive PCa subtypes that are associated with higher cancer-specific mortality but can be missed during biopsy or
Mira Keyes, MD, FRCPC, a Clinical Professor at the University of British Columbia (UBC) and a radiation oncologist at the A new treatment approach for prostate cancer is gaining attention: irreversible electroporation (IRE). In this episode of UroNurse Focal Therapy for Men with Intermediate Risk Prostate Cancer
In this video, PCRI's Alex and Medical Oncologist Mark Scholz, MD, discuss the first steps and prognosis for men who have been Choosing a Treatment for Intermediate Risk Prostate Cancer | Prostate Cancer Staging Guide Radiology In a Minute provides short summaries of current radiology research. Follow @radiology_rsna on twitter for updates Link
Intermediate Risk Prostate Cancer Dr. Neil Desai, a radiation oncologist with UT Southwestern, shares his perspectives on radiation therapy indications, algorithms,
PCRI's Executive Director, Mark Scholz, MD, talks about stereotactic body radiation therapy (SBRT) as a treatment for men with FTS 15 - Day 2 - Focal Therapy for Intermediate Risk Prostate Cancer
Intermediate Risk Prostate Cancer - A New Management Method? Intermediate risk prostate cancers are the most frequently treated prostate cancers. They are cancers that are confined to the prostate, often are Gleason 7 Active Surveillance in Favorable Intermediate-Risk Prostate Cancer
Understanding Treatment for High-Risk Prostate Cancer | Prostate Cancer Staging Guide High Risk Prostate Cancer: Surgery vs. Radiation | Genomic Tests | Mark Scholz, MD | PCRI MUSC Hollings Cancer Center radiation oncologist Dr. David Marshall reviews the treatment options for intermediate risk prostate
Dr. Steve Shak, Chief Medical Officer at Exact Sciences discusses the publication of new analyses of two clinical studies that Decipher, SelectMDx, and 4K Score in Active Surveillance & Intermediate Prostate Cancer | PCRI Effect of Standard vs Dose-Escalated Radiation Therapy for Patients
Modern active surveillance in low- and intermediate-risk prostate Role of genomic profiling in the management of intermediate-risk prostate cancer Dr. John Cheville a Consultant in Pathology, and Dr. George Vasmatzis, a Consultant in Molecular Medicine, and Co-directors of
Dr. Mark Emberton presented "Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, gives an overview of treatment options for high-risk localized Management of Favorable Intermediate Risk Prostate Cancer by Dr. Jarrah Aburezq, Urology Resident (PGY3), Department of
Radiotherapy for Unfavorable Intermediate Prostate Cancer w/ Dr. Neil Desai | BackTable Ep. 41 Which Treatment is Better for Unfavorable Intermediate Risk Prostate Cancer, Cyberknife or surgery? Prostate cancer - Diagnosis and treatment - Mayo Clinic
SBRT for the Intermediate-Risk (Teal) Prostate Cancer | Prostate Cancer Staging Guide Alex and Dr. Scholz give an overview of which features distinguish the different stages of Teal stage (intermediate-risk) prostate
If you have prostate cancer, Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses novel tools for the management of
Determining How Aggressively to Treat Relapsed & Intermediate-Risk Prostate Cancer | Mark Scholz, MD Intermediate Risk Prostate Cancer: Paul Nguyen, MD
This video will discuss the the success rate and the side effects with Cyberknife and surgery for unfavorable Intermediate risk Intermediate Risk Prostate Cancer: Felix Feng, MD Christopher J. Kane, MD, FACS, the Dean of Clinical Affairs at the University of California San Diego School of Medicine, and the
Debate: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer - Surgery Treatment options for intermediate-risk patients range from active surveillance to partial gland ablation, radical prostatectomy, and various radiotherapy
Low, Intermediate & High Risk Prostate Cancer | Tucker Medical Shorts Active surveillance (AS) has become a widely accepted management strategy for men with low-risk localized prostate cancer (PC), aiming to Intermediate Risk Prostate Cancer: Daniel Spratt, MD
Prostate Cancer Clinical Trial NRG-GU010 (Part 3/3) Intermediate risk prostate cancers are usually those that have grown big enough for a doctor to feel on a physical exam and see on an imaging test. Prostate Cancer Clinical Trial NRG-GU010 (Part 1/3)
PCRI's Executive Director, Mark Scholz, MD, talks about proton therapy as a treatment for men with the Teal stage of prostate Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13
Point-Counterpoint: Active Surveillance for Intermediate-Risk Prostate Cancer - Pro In this episode of BackTable Urology, Dr. Aditya Bagrodia discusses radiation therapy for favorable intermediate-risk prostate Debate: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer– Brachytherapy
This randomized clinical trial showed that the OS of men treated for localized intermediate-risk prostate cancer was not improved with radiation Managing Unfavorable Intermediate Risk Prostate Cancer: Expert Guidance with Dr. Art Rastinehad
PCRI's Executive Director, Mark Scholz, MD, compares different treatments for men with Teal stage (intermediate-risk) prostate Dr. Larry Goldenberg, Professor & Head, Department of Urologic Sciences, and Director of Development, the Vancouver Prostate Intermediate Risk Prostate Cancer: What It Is, How It's Treated
What does it mean when prostate cancer is Low Risk, Intermediate Risk, or High Risk? In this short video, Dr. Tucker breaks down A new treatment combines radiation therapy with irreversible electroporation (IRE) to target the most aggressive part of cancer.
An Overview of Gleason 3+4 & Gleason 4+3 Prostate Cancer | Ask A Prostate Expert, Mark Scholz, MD Irreversible Electroporation Shows Promise for Intermediate-Risk Prostate Cancer Dan Reznicek, MD, a urologist from Bellingham, WA, goes over prostate cancer risk stratification. Prostate Cancer risk can vary
Description: Uncover the nuances of favorable intermediate-risk prostate cancer in this detailed video. Join leading oncologist as Join Dr. Art Rastinehad in this enlightening session tailored for patients facing unfavorable intermediate risk prostate cancer. Omar Mian, MD, PhD, Assistant Professor of Medicine at Case Western Reserve University discusses the intermediate risk
Many prostate cancers fall in the "intermediate-risk" category. This means that they can vary in size but can spread outside the prostate. There are Management of Favorable Intermediate Risk Prostate Cancer
Daniel Spratt, MD, Professor of Radiation Oncology at University of Michigan discusses the intermediate risk prostate cancer Neil Desai, MD, MHS, Associate Professor of Radiation and Oncology specializing in the treatment of GU malignancies at UT Dr. Mark Scholz is a medical oncologist specializing exclusively in the treatment of prostate cancer, and in this video he answers
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, w/ Michael Leapman, MD Active surveillance or intervention in intermediate-risk prostate cancer FTS 15 - Day 2 - Focal Therapy for Intermediate Risk Prostate Cancer Key Points: • Focal Therapy vs. Radical Treatments: The
How Do We Determine Prostate Cancer Risk Intermediate-risk Prostate Cancer: Stratification and Management
The population of patients with intermediate-risk prostate cancer are a large and heterogeneous group with highly variable prognoses, Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRI 3+4=7 #ProstateCancer | Active Surveillance vs. Focal Therapy | #MarkScholzMD #AlexScholz #PCRI
Intermediate Risk Prostate Cancer: Omar Mian, MD, PhD prostate cancer. How do you know how fast my cancer is growing? If you have low to intermediate risk prostate cancer, there are genomic
"I have intermediate-risk prostate cancer — how can RT + IRE improve my treatment?" Utility of PSMA-PET in Intermediate Risk Prostate Cancer Patients: Part 1 "I have intermediate-risk prostate cancer—can IRE plus lower-dose radiation improve my outcomes?"
PCRI's Alex asks Dr. Scholz questions from our YouTube comments on the side effects of hormone therapy, whether it is The RTIRE trial is studying whether combining IRE with lower-dose radiation can improve outcomes for men with intermediate-risk
Proton Therapy Intermediate-Risk (Teal) Prostate Cancer | Prostate Cancer Staging Guide Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Patients with Gleason 3+4=7 represent one of the largest "grey areas" in the world of prostate cancer. For patients with Gleason
Intermediate risk prostate cancer: definition, workup and staging, treatment options (active surveillance, radiation therapy, Medical Oncologist, Mark Scholz, MD, answers patients' questions about the genomic tests used in prostate cance. One Intermediate-Risk Prostate Cancer: What to Know - GoodRx
Purpose: Active surveillance (AS) is an option for the initial management of early-stage prostate cancer. Current risk stratification schema Outcomes of active surveillance for men with intermediate-risk
Point-Counterpoint: Active Surveillance for Intermediate-Risk Prostate Cancer - Con Intermediate Risk Prostate Cancer - Prostate Cancer | UCLA Health
James A. Eastham, MD, FACS, considers how to select candidates for active surveillance in the intermediate-risk prostate cancer Prostate Cancer: Biomarkers, Low, Intermediate, & High-Risk
In this inaugural episode of The UroOnc Minute from Urology Times, host Adam Weiner, MD, sits down with Michael S. Leapman, Intermediate risk prostate tumors contain lethal subtypes - Frontiers
Paul Nguyen, MD, Professor of Radiation Oncology at Harvard Medical School discusses the intermediate risk prostate cancer Unfavorable Intermediate (UFI)-Risk Prostate Cancer Testing Navigating Prostate Cancer: Understanding Favorable Intermediate-Risk Cancer by Dr. Tay Kae Jack
Intermediate risk prostate cancer This study is for men with unfavorable intermediate risk prostate cancer and high gene scores.
Medical oncologist Mark Scholz, MD answers patient's questions from our YouTube comments on the topics of active surveillance PCRI's Executive Director, Mark Scholz, breaks down Azure (high-risk) into subtypes and discusses the subtle differences
Gleason 4+3 = 7 #prostatecancer | First Steps | #markscholzmd | #pcri Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Johan Stranne, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden, discusses the role of active surveillance versus The role of radiation in managing high-risk localized prostate cancer
Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses the The NRG-GU010 trial is testing standard radiation with hormone therapy, versus standard radiation alone. PIs: Neil Desai and